BACKGROUND: Locoregional recurrences are often observed after esophagectomy with lymphadenectomy. The treatment strategy for these patients has not been established completely. The purpose of this study was to evaluate the prognosis of salvage lymphadenectomy through the cervical incision for cervical and cervicothoracic recurrences. METHODS: We retrospectively reviewed patients underwent initial esophagectomy and then salvage lymphadenectomy in Fudan University Shanghai Cancer Center during July 2006 and September 2016. Survival curve was calculated by Kaplan-Meier method. Prognostic factors for post-salvage lymphadenectomy overall survival (PSL-OS) were identified by univariate and multivariate analyses. RESULTS: The median disease-free survival (DFS) was 8 months. The median PSL-OS was 40 months (95% CI: 8.850-71.150). The 1-, 2-, 3- and 5-year PSL-OS rate were 87%, 58%, 52% and 41%, respectively. Univariate and multivariate analyses confirmed the initial TNM stage was the only independent prognostic factor for PSL-OS (P=0.000 by log-rank test, P=0.009 by Cox hazards model, HR 3.999, 95% CI: 1.413-11.316) among these patients. CONCLUSIONS: PSL survival could be considerable for patients with early initial tumor stage. Prospective studies are warranted to clarify the value of salvage lymphadenectomy.
BACKGROUND: Locoregional recurrences are often observed after esophagectomy with lymphadenectomy. The treatment strategy for these patients has not been established completely. The purpose of this study was to evaluate the prognosis of salvage lymphadenectomy through the cervical incision for cervical and cervicothoracic recurrences. METHODS: We retrospectively reviewed patients underwent initial esophagectomy and then salvage lymphadenectomy in Fudan University Shanghai Cancer Center during July 2006 and September 2016. Survival curve was calculated by Kaplan-Meier method. Prognostic factors for post-salvage lymphadenectomy overall survival (PSL-OS) were identified by univariate and multivariate analyses. RESULTS: The median disease-free survival (DFS) was 8 months. The median PSL-OS was 40 months (95% CI: 8.850-71.150). The 1-, 2-, 3- and 5-year PSL-OS rate were 87%, 58%, 52% and 41%, respectively. Univariate and multivariate analyses confirmed the initial TNM stage was the only independent prognostic factor for PSL-OS (P=0.000 by log-rank test, P=0.009 by Cox hazards model, HR 3.999, 95% CI: 1.413-11.316) among these patients. CONCLUSIONS: PSL survival could be considerable for patients with early initial tumor stage. Prospective studies are warranted to clarify the value of salvage lymphadenectomy.
Authors: M Yano; K Takachi; Y Doki; I Miyashiro; K Kishi; S Noura; H Eguchi; T Yamada; M Ohue; H Ohigashi; Y Sasaki; O Ishikawa; T Matsunaga; S Imaoka Journal: Dis Esophagus Date: 2006 Impact factor: 3.429
Authors: Vera Oppedijk; Ate van der Gaast; Jan J B van Lanschot; Pieter van Hagen; Rob van Os; Caroline M van Rij; Maurice J van der Sangen; Jannet C Beukema; Heidi Rütten; Patty H Spruit; Janny G Reinders; Dick J Richel; Mark I van Berge Henegouwen; Maarten C C M Hulshof Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: H Shiozaki; M Yano; T Tsujinaka; M Inoue; S Tamura; Y Doki; T Yasuda; Y Fujiwara; M Monden Journal: Dis Esophagus Date: 2001 Impact factor: 3.429
Authors: Y Chen; Y Lu; Y Wang; H Yang; Y Xia; M Chen; H Song; T Li; D Li; J Wang; S Li; J Wang Journal: Dis Esophagus Date: 2012-10-22 Impact factor: 3.429